Patents Assigned to Burnham Institute for Medical Research
  • Patent number: 9951122
    Abstract: The invention provides human scFv antibodies and monoclonal antibodies that neutralize influenza virus. Also provided are methods of treating and/or preventing a influenza related disease or disorder such bird flu The invention also provides methods of vaccinating a patient against influenza. Also provided are methods of diagnosing influenza-related diseases or disorders and methods of detecting the presence of a influenza in a sample.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: April 24, 2018
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., BURNHAM INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Wayne A. Marasco, Jianhua Sui, Robert C. Liddington
  • Patent number: 9610359
    Abstract: Disclosed are conjugates comprising the annexin 1-binding peptide IFLLWQR covalently linked to a therapeutic or detectable agent. Also disclosed are compositions comprising a moiety and a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Also disclosed are isolated nucleic acids comprising a nucleic acid sequence encoding a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Also disclosed are methods comprising administering to a subject a composition comprising a moiety and a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Also disclosed are methods of targeting a tumor cell in a subject comprising administering to the subject a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: April 4, 2017
    Assignees: Burnham Institute for Medical Research, Hamamatsu University School of Medicine
    Inventors: Michiko Fukuda, Kazuhiro Sugihara, Naohira Kanayama
  • Patent number: 9598670
    Abstract: We used ACCUTASE®, a commercially available cell detachment solution, for single cell propagation of pluripotent hESCs. Unlike trypsin dissociation, ACCUTASE® treatment does not significantly affect the plating efficiency of hESC dissociation into single cells. Cultures dissociated with ACCUTASE® to single cells at each passage maintain a higher proportion of pluripotent cells as compared to collagenase-passaged hESCs. ACCUTASE®-treated hESCs can be grown to a high density as monolayers, and yet retain their pluripotency.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: March 21, 2017
    Assignee: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Alexey Terskikh, Ruchi Bajpai
  • Patent number: 9186093
    Abstract: We have developed a reduced Drosophila heart preparation in which dissection of the fly heart removes nervous system input and reveals its inherent myogenic activity, which can be preserved for several hours. High speed image capture combined with computer-based analytical packages allows us to generate the equivalent of M-mode traces obtained from ultrasounds of human hearts.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: November 17, 2015
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, BURNHAM INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Rolf Bodmer, Karen Ocorr, Martin Fink
  • Patent number: 9157061
    Abstract: We used ACCUTASE®, a commercially available cell detachment solution, for single cell propagation of pluripotent hESCs. Unlike trypsin dissociation, ACCUTASE® treatment does not significantly affect the plating efficiency of hESC dissociation into single cells. Cultures dissociated with ACCUTASE® to single cells at each passage maintain a higher proportion of pluripotent cells as compared to collagenase-passaged hESCs. ACCUTASE®-treated hESCs can be grown to a high density as monolayers, and yet retain their pluripotency.
    Type: Grant
    Filed: June 20, 2011
    Date of Patent: October 13, 2015
    Assignee: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Alexey Terskikh, Ruchi Bajpai
  • Patent number: 9115061
    Abstract: Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: wherein each R is independently selected from the group consisting of H, C(O)X, C(O)NHX, NH(CO)X, SO2NHX, and NHSO2X, wherein X is selected from the group consisting of an alkyl, a substituted alkyl, an aryl, a substituted aryl, an alkylaryl, and a heterocycle. Compounds of group A may be used for treating various diseases or disorders, such as cancer.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: August 25, 2015
    Assignee: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Maurizio Pellecchia, John C. Reed
  • Patent number: 9012217
    Abstract: Methods and small molecule compounds for stem cell differentiation are provided.
    Type: Grant
    Filed: September 16, 2009
    Date of Patent: April 21, 2015
    Assignees: Burnham Institute for Medical Research, Human Biomolecular Research Institute
    Inventors: Mark Mercola, Marcia Dawson, John Cashman, Paul J. Bushway
  • Patent number: 8760756
    Abstract: In an automated scanning cytometry system, chromatic aberration is used for multiplanar image acquisition.
    Type: Grant
    Filed: October 14, 2009
    Date of Patent: June 24, 2014
    Assignee: Burnham Institute for Medical Research
    Inventors: Jeffrey H. Price, Martin Weinigel, Derek N. Fuller, Albert L. Kellner
  • Publication number: 20140011982
    Abstract: The invention provides human scFv antibodies and monoclonal antibodies that neutralize influenza virus. Also provided are methods of treating and/or preventing a influenza related disease or disorder such bird flu The invention also provides methods of vaccinating a patient against influenza. Also provided are methods of diagnosing influenza-related diseases or disorders and methods of detecting the presence of a influenza in a sample.
    Type: Application
    Filed: August 12, 2013
    Publication date: January 9, 2014
    Applicants: BURNHAM INSTITUTE FOR MEDICAL RESEARCH, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Wayne A. Marasco, Jianhua Sui, Robert C. Liddington
  • Patent number: 8436207
    Abstract: Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: wherein each R is independently H, C(O)X, C(O)NHX, NH(CO)X, SO2NHX, or NHSO2X, wherein X is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, heterocycle, or substituted heterocycle. Compounds of group A may be used for treating various diseases or disorders, such as cancer.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: May 7, 2013
    Assignee: Burnham Institute for Medical Research
    Inventor: Maurizio Pellecchia
  • Patent number: 8258321
    Abstract: The present invention provides compounds having the general structure A, or a pharmaceutically acceptable derivatives thereof: wherein R is an alkyl group, and R1 comprises at least one moiety selected from a group consisting of an alkyl, an alkenyl, an aryl, a heterocycle, hydroxyl, ester, amido, aldehyde, and a halogen.
    Type: Grant
    Filed: October 30, 2008
    Date of Patent: September 4, 2012
    Assignees: Burnham Institute for Medical Research, The Texas A&M University System
    Inventors: Jeffrey W. Smith, Daniel Romo, Gil Ma, Manuel Zancanella
  • Patent number: 8188221
    Abstract: The present invention relates to a peptide, which specifically homes to the intracranial, early stage astrocytoma model that grows as islets and harbors co-opted tumor vessels in the brain. The peptide finds its use in targeted delivery of therapeutic substances to invasive brain cancer or metastatic brain lesions as such and in combination with conventional therapies, such as surgery and radiation, and anti-angiogenic therapies, and as a tool in diagnosis of, e.g., invasive brain cancer or metastatic brain lesions.
    Type: Grant
    Filed: May 8, 2009
    Date of Patent: May 29, 2012
    Assignees: Burnham Institute for Medical Research, The Regents of the University of California, UCSF
    Inventors: Pirjo Laakkonen, Erkki Ruoslahti, Gabriele Bergers
  • Publication number: 20120128684
    Abstract: Disclosed are antibodies that bind to the stem region of influenza hemagglutinin in the neutral pH conformation, hemagglutinin epitopes in the stem region, and methods of making and using both.
    Type: Application
    Filed: August 25, 2009
    Publication date: May 24, 2012
    Applicants: Burnham Institute for Medical Research, Dana-Farber Cancer Institute, Inc.
    Inventors: Wayne Marasco, Jianhua Sui, Robert C. Liddington
  • Patent number: 8178349
    Abstract: This invention provides pure populations of neural precursor cells, capable of differentiation into neurons, glial cells, and astrocytes. The populations are obtained by culturing stem cell populations (such as embryonic stem cells) in a cocktail of growth conditions that initiates differentiation, and establishes the neural precursor population. The precursors can be further differentiated in culture into a variety of different neural phenotypes. The neural precursors can be generated in pure form (at least 99%) and in large quantities for use in drug screening and the treatment of neurological disorders.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: May 15, 2012
    Assignee: Burnham Institute For Medical Research
    Inventors: Alexy Terskikh, Ruchi Bajpai
  • Patent number: 8168391
    Abstract: The present invention provides screening methods for the detection of agents that affect various aspects of ?-cell biology, particularly insulin gene expression. Screening methods are also provided for detection of agents that affect ?-cell differentiation from progenitor cells. Additionally, agents identified using such methods are provided and are useful for increasing insulin gene expression and reducing lipotoxicity.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: May 1, 2012
    Assignees: Burnham Institute for Medical Research, The Regents of the University of California
    Inventors: Fred Levine, Pamela Itkin-Ansari, Mark Mercola
  • Publication number: 20120015992
    Abstract: Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: wherein each R is independently H, C(O)X, C(O)NHX, NH(CO)X, SO2NHX, or NHSO2X, wherein X is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, heterocycle, or substituted heterocycle. Compounds of group A may be used for treating various diseases or disorders, such as cancer.
    Type: Application
    Filed: September 21, 2011
    Publication date: January 19, 2012
    Applicant: Burnham Institute for Medical Research
    Inventor: Maurizio Pellecchia
  • Patent number: 8039668
    Abstract: Methods of using apogossypol and its derivatives for treating inflammation is disclosed. Also, there is described a group of compounds having structure A, or a pharmaceutically acceptable salt, hydrate, N-oxide, or solvate thereof are provided: wherein each R is independently H, C(O)X, C(O)NHX, NH(CO)X, SO2NHX, or NHSO2X, wherein X is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, alkylaryl, substituted alkylaryl, heterocycle, or substituted heterocycle. Compounds of group A may be used for treating various diseases or disorders, such as cancer.
    Type: Grant
    Filed: April 14, 2010
    Date of Patent: October 18, 2011
    Assignee: Burnham Institute for Medical Research
    Inventor: Maurizio Pellecchia
  • Patent number: 8022246
    Abstract: Neurite outgrowth-promoting prostaglandins (NEPPs) and other electrophilic compounds bind to Keap1, a negative regulator of the transcription factor Nrf2, and prevent Keap1-mediated inactivation of Nrf2 and, thus, enhance Nrf2 translocation into the nucleus of neuronal cells. Therefore, neuroprotective compositions and related methods are provided that employ such neuroprotective compounds, and prodrugs of such compounds, to cause dissociation of Nrf2 from a Keap1/Nrf2 complex.
    Type: Grant
    Filed: October 10, 2007
    Date of Patent: September 20, 2011
    Assignee: The Burnham Institute for Medical Research
    Inventors: Stuart Lipton, Takumi Satoh
  • Patent number: 8008354
    Abstract: Methods of identifying death receptor sensitizing compounds and methods of using death receptor sensitizing compounds are provided.
    Type: Grant
    Filed: January 11, 2007
    Date of Patent: August 30, 2011
    Assignee: Burnham Institute for Medical Research
    Inventors: Aaron D Schimmer, John C. Reed
  • Patent number: 7982002
    Abstract: In accordance with the present invention, there are provided novel Siah-Mediated-Degradation-Proteins (SMDPS) and/or SCF-Complex Proteins (SCPs). Nucleic acid sequences encoding such proteins and assays employing same are also disclosed. The invention SMDPs and/or SCPs can be employed in a variety of ways, for example, for the production of anti-SMDP and/or SCP antibodies thereto, in therapeutic compositions, and methods employing such proteins and/or antibodies for drug screening, functional genomics and other applications. Also provided are transgenic non-human mammals that express the invention protein. Also provided are compositions and methods for targeting the destruction of selected polypeptides in eukaryotic cells based on the ubiquitin-independent mechanism by which ornithine decarboxylase is degraded by the 26S proteasome.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: July 19, 2011
    Assignee: Burnham Institute for Medical Research
    Inventors: John C. Reed, Shu-ichi Matsuzawa